Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib and Letrozole in ER/PR-positive Ovarian Cancer
NCT03936270Phase 2Completed
- Sponsor
- Latin American Cooperative Oncology Group
- Start
- Mar 2020
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of palbociclib in ovarian cancer, sponsored by Latin American Cooperative Oncology Group. Primary endpoint: Progression-Free Survival at 12 weeks. Started Mar 2020; status: completed.
02
Drugs
palbociclib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT03936270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03936270.